Awaiting product image

Ihc – Breast Cancer Prognosis Basic Panel# 1a (Er, Pr, Dna Ploidy / S-Phase)

₹5,000.00

15 minutes
Categories: ,

This test combines Immunohistochemistry (IHC) and flow cytometry techniques to evaluate several important prognostic markers in breast cancer:

• ER (Estrogen Receptor) and
• PR (Progesterone Receptor): Hormone receptors indicating whether the cancer is likely to respond to hormone therapy.
• DNA Ploidy: Measures the DNA content of tumor cells, classifying them as diploid (normal) or aneuploid (abnormal), which reflects genetic stability.
• S-Phase Fraction: Indicates the percentage of tumor cells in the DNA synthesis phase of the cell cycle—higher values suggest a faster-growing, more aggressive tumor.

Together, these markers help determine tumor behavior, treatment responsiveness, and overall prognosis.

Enquiry Here

    Description

    Why It’s Done:

    This panel is used to:
    • Assess hormone receptor status (ER/PR) to determine suitability for hormone therapy.
    • Evaluate tumor aggressiveness through DNA ploidy and S-phase data.
    • Predict prognosis—tumors with abnormal DNA ploidy and high S-phase fraction may have a worse prognosis.
    • Help guide personalized treatment planning, especially in early-stage breast cancer.

    Preparation:

    • No special preparation is needed from the patient for the test itself.
    • The test is performed on a breast tissue sample, typically obtained during a biopsy or surgery.
    • Follow your doctor’s instructions if you are undergoing a biopsy procedure (such as fasting or medication adjustments).
    • Inform your physician about any current medications, especially if undergoing sedation or anesthesia.

    Related products